This presentation has 2 parts. In the first part of this presentation, Prof. Nobuharu Tamaki discusses the diagnostic utility of PIVKA-II in HCC, and the potential etiologies where PIVKA-II may be useful in surveillance and detection of HCC. In the second half, he discusses the correlation between PIVKA-II levels and treatment outcomes, and how PIVKA-II can potentially be used for treatment monitoring in HCC….
Cancer Type: Liver
HCC Patient Journey and biomarkers’ roles in the HCC management
Detection of HCC at early stages remains a challenge, with less than 20% of patients being diagnosed at an early stage, when they can benefit from potentially curative therapies(1). In this presentation, Prof. Tawesak Tanwandee discusses the role of tumour markers for early diagnosis of HCC, as well as prognosis and response to treatment. …
The clinical utility of HCC algorithms as aids in the diagnosis of HCC
In this presentation, Prof. Ming Lung Yu discusses the results of his study, which aims to address the diagnostic accuracy of HCC using Elecsys GAAD algorithmic score as compared to AFP and PIVKA-II, with or without the complementation of sonography. …
Review of PIVKA-II expert consensus from APASL presentation
In this presentation, Prof. Do Young Kim reviews the results of the APAC expert consensus study on the utilization of PIVKA-II in the surveillance and monitoring of hepatocellular carcinoma in APAC. The objective of this study is to discuss the clinical usefulness and value of PIVKA-II in APAC for the surveillance and treatment monitoring of HCC, its benefits and limitations, and further steps required to improve its utility. His results were also presented during APASL 2022….
APASL 2022 Seoul
The liver cancer landscape has been undergoing a period of rapid transformation. From early detection of HCC using new biomarkers, to new immunotherapy treatment options. Watch the APASL 2022 webinars to hear experts share updates in the diagnosis and testing, and treatment of HCC. …
APPLE 2021 – Biomarker In HCC Surveillance And Treatment: The New Evidence On The Horizon
Join the webinar to hear speakers Prof. Henry Chan and Prof. Hui Chuan Sun as they discuss the use of PIVKA-II and GAAD score as promising tools for HCC surveillance, and the value of AFP and PIVKA-II in HCC treatment monitoring. …